PCN92 INOTUZUMAB OZOGAMICIN VERSUS STANDARD CHEMOTHERAPY FOR RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A COST-UTILITY ANALYSIS FROM THE PERSPECTIVE OF NATIONAL HEALTH INSURANCE ADMINISTRATION IN TAIWAN